TYRA

TYRA is a clinical-stage precision-oncology company built around FGFR biology and its in-house 'SNÅP' platform — by its own 10-K description it has no approved products and no revenue in any year shown (FY2021–FY2025 revenue is blank). Every dollar of value here rests on pipeline candidates that are still in preclinical/clinical development, and the filing's forward-looking language leans entirely on 'the timing and likelihood of regulatory filings and approvals' and 'the safety and therapeutic benefits of our product candidates' — none of which can be underwritten from the financials provided. That is the definition of unknowable, binary risk for an outside investor.

The balance sheet is genuinely the bright spot and the reason this isn't a 'sell.' Liabilities are just $23.4M against $259M of equity (0.09x), there is effectively no debt, and current assets of $265M dwarf the $18.1M of current liabilities. Cash & equivalents are $77.4M, but the gap up to $265M in current assets implies a sizable marketable-securities balance. Against an FY2025 operating cash burn of -$95.1M, that funds roughly two years of operations — adequate, but with burn accelerating (R&D +28.5%, net loss -$120M, the fifth straight year of widening losses from -$26.3M in FY2021) a dilutive raise is a question of when, not if.